575: 17-hydroxyprogesterone caproate for preterm rupture of membranes: a randomized, double-blind, placebo-controlled clinical trial - 19/12/14
Doi : 10.1016/j.ajog.2014.10.781
C Andrew Combs 1, Thomas Garite 2, Kimberly Maurel 1, Diana Abril 1, Anita Das 3, William Clewell 4, Kent Heyborne 5, Helen How 6, Wilson Huang 7, David Lewis 8, George Lu 9, Hugh Miller 10, Michael Nageotte 11, Richard Porreco 12, Asad Sheikh 13, Lan Tran 14
For the
For the
Obstetrix Collaborative Research Network1
1 Obstetrix Medical Group, the Center for Research, Education, & Quality, Mednax, Inc., Sunrise, FL
2 Obstetrix Medical Group and University of California, Irvine, CA
3 InClin, San Mateo, CA
4 Obstetrix Medical Group (Phoenix Perinatal Associates), Phoenix, AZ
5 Obstetrix Medical Group and Denver Health, Denver, CO
6 Norton Healthcare, Louisville, KY
7 High Risk Pregnancy Center, Las Vegas, NV
8 University of South Alabama, Mobile, AL
9 Obstetrix Medical Group, Kansas City, MO
10 Obstetrix Medical Group, Tucson, AZ
11 Obstetrix Medical Group, Long Beach, CA
12 Obstetrix Medical Group, Denver, CO
13 Spectrum Health, Grand Rapids, MI
14 Obstetrix Medical Group, Seattle, WA
Le texte complet de cet article est disponible en PDF.
Plan
© 2015
Publié par Elsevier Masson SAS.
Vol 212 - N° 1S
P. S287 - janvier 2015 Retour au numéro
Article précédent
- 574: Efficacy of hydralazine, labetalol, and nifedipine for the acute reduction of severe hypertension in pregnancy: a systematic review
- Brad Holbrook, Pranita Nirgudkar, Ellen Mozurkewich
- 576: Clinical vs pathologic chorioamnionitis and risk of adverse neonatal & childhood outcomes
- Christina Herrera, Michael Varner, Tracy Manuck
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?